SPECT-CT and PET-CT in oncology - An overview

Current Medical Imaging Reviews

Volumn 7, Issue 3, 2011, Pages 202-209

  Basu, Sandip ^a   Alavi, Abass ^b  

^a TATA MEMORIAL HOSPITAL   (India)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer; Hybrid imaging; PET CT; SPECT CT

Indexed keywords

CAPROMAB PENDETIDE IN 111; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; LUTETIUM 177; OCTREOTIDE; PENTETREOTIDE IN 111; YTTRIUM 90;

ANATOMICAL CONCEPTS; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COLORECTAL CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; DOSIMETRY; EYE TOXICITY; FALSE POSITIVE RESULT; FOLLOW UP; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HYPERMETABOLISM; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE QUALITY; INCIDENCE; INTERMETHOD COMPARISON; LUNG CARCINOMA; LYMPHEDEMA; LYMPHOMA; LYMPHOSCINTIGRAPHY; MELANOMA; METASTASIS; MORBIDITY; NEUROENDOCRINE TUMOR; ONCOLOGY; PANCREAS TUMOR; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOISOTOPE DIAGNOSIS; RADIOISOTOPE THERAPY; REVIEW; RISK REDUCTION; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

EID: 79961068099     PISSN: 15734056     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/157340511796411168     Document Type: Review

References (48)

1. Lerman H, Metser U, Lievshitz G, et al. Lymphoscintigraphic sentinel node identification in patients with breast cancer: the role of SPECT/CT. Eur J Nucl Med Mol Imaging 2006; 33: 329-37
2. Lerman H, Lievshitz G, Zak O, et al. Improved sentinel node identification by SPECT/CT in overweight patients with breast cancer. J Nucl Med 2007; 48: 201-6
3. van der Ploeg IM, Valdés Olmos RA, Nieweg OE, et al. The additional value of SPECT/CT in lymphatic mapping in breast cancer and melanoma. J Nucl Med 2007; 48: 1756-60
4. van der Ploeg IM, Nieweg OE, Kroon BB, et al. The yield of SPECT/CT for anatomical lymphatic mapping in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2009; 36: 903-9
5. van der Ploeg IM, Olmos RA, Kroon BB, Rutgers EJ, Nieweg OE. The hidden sentinel node and SPECT/CT in breast cancer patients. Eur J Nucl Med Mol Imaging 2009; 36(1): 6-11
6. Valdés Olmos RA, Vidal-Sicart S, Nieweg OE. SPECT/CT and real-time intraoperative imaging: new tools for sentinel node localization and radioguided surgery? Eur J Nucl Med Mol Imaging. 2009; 36(1): 1-5
7. Basu S, Alavi A. Multifaceted role of lymphatic mapping by SPECT/CT hybrid imaging in the multimodality management of patients with cancer. Eur J Nucl Med Mol Imaging. 2009; 36(6): 1017-8
8. Cheville AL, Das I, Srinivas S, et al. A pilot study to assess the utility of SPECT/CT-based lymph node imaging tolocalize lymph nodes that drain the arm in patients undergoing treatment for breast cancer. Breast Cancer Res Treat. 2009. [Epub ahead of print]
9. Leijte JA, Valdés Olmos RA, Nieweg OE, Horenblas S. Anatomical mapping of lymphatic drainage in penile carcinoma with SPECT/CT: implications for the extent of inguinal lymph node dissection. Eur Urol. 2008; 54(4): 885-90
10. Horger M, Bares R. The role of single-photon emission computed tomography/computed tomography in benign and malignant bone disease, Semin Nucl Med 2006; 36: 286-294
11. Utsunomiya D, Shiraishi S, Imuta M, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology 2006; 238(1): 264-71
12. Romer W, Nömayr A, Uder M, et al. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients, J Nucl Med 2006; 47(7): 1102-6
13. Dore F, Filippi L, Biasotto M, Chiandussi S, Cavalli F, Di Lenarda R. Bone scintigraphy and SPECT/CT of bisphosphonate-induced osteonecrosis of the jaw. J Nucl Med 2009; 50(1): 30-5
14. Y. Krausz, Z. Keidar and I. Kogan et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours, Clin Endocrinol 2003; 59(5): 565-73
15. A.C. Pfannenberg, S.M. Eschmann and M. Horger, et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms, Eur J Nucl Med Mol Imaging 2003;, 30(6): 835-43
16. P.G. Hillel, E.J.R. van Beek and C. Taylor, et al. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours, Clin Radiol 2006; 61(7): 579-87
17. Castaldi P, Rufini V, Treglia G, et al. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours. Radiol Med 2008; 113(7): 1056-67
18. Perri M, Erba P, Volterrani D, et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging 2008; 52(4): 323-33
19. Boucek JA, Turner JH. Validation of prospective whole-body bone marrowdosimetry by SPECT/CT multimodality imaging in (131)Ianti-CD20 rituximabradioimmunotherapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2005; 32(4): 458-69
20. He B, Wahl RL, Sgouros G, et al. Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning-patient studies. MedPhys 2009; 36(5): 1595-601
21. Kwekkeboom D.J., Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors, J Clin Oncol 2005; 23(12): 2754-62
22. Machac J, Weintraub J, Nowakowski FS, et al. Variations in liver perfusion patterns in patients with liver tumors undergoing therapy with yttrium-90 microspheres, studied with SPECT-CT, J Nucl Med) 2007; 396P
23. Raphael B, Akhurst T, Rao V, et al. Hepatic arterial pump perfusion. The value of macroaggregated albumin (MAA) SPECT/CT in comparison with planar and SPECT imaging, J Nucl Med 2007; 390
24. Sodee DB, Nelson AD, PF Faulhaber, et al. Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer 2005; 3(4): 230-8
25. Wong TZ, Turkington TG, TJ. Polascik, et al. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology, AJR Am J Roentgenol 2005; 184(2): 676-80
26. Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol 2011; 12(2): 181-91
27. Basu S, Alavi A. Revolutionary impact of PET and PET-CT on the day-to-day practice of medicine and its great potential for improving future health care. Nucl Med Rev Cent East Eur 2009; 12(1): 1-13
28. Basu S, Alavi A. Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med 2008; 49(10): 17N-21N, 37N
29. De Wever W, Stroobants S, Coolen J, Verschakelen JA. Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J 2009; 33(1): 201-12
30. Francis DL, Visvikis D, Bomanji JB, et al. The impact of FDG PET/CT in colorectal cancer: an outcome study [abstract]. J Nucl Med 2003; 44: 26P
31. Burger I, Goerres GW, von Schulthess GK, Seifert B, Hany TF. PET/CT: Diagnostic improvement in recurrent colorectal carcinoma compared to PET alone. Radiology 2002; 225(suppl P):242
32. Orlacchio A, Schillaci O, Fusco N, et al. Role of PET/CT in the detection of liver metastases from colorectal cancer. Radiol Med 2009; 114(4): 571-85
33. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring ofimatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45: 357-65
34. Pineau BC, Paskett ED, Chen GJ, et al. Virtual colonoscopy using oral contrast compared with colonoscopy for the detection of patients with colorectal polyps. Gastroenterology 2003; 125: 304-10
35. Mainenti PP, Salvatore B, D'Antonio D, et al. PET/CT colonogra-phy in patients with colorectal polyps: A feasibility study. Eur J Nucl Med Mol Imaging 2007; 34(10): 1594-603
36. Kinner S, Antoch G, Bockisch A, Veit-Haibach P. Whole-body PET/CT-colonography: a possible new concept for colorectal cancer staging. Abdom Imaging. 2007; 32(5): 606-12
37. Veit-Haibach P, Kuehle CA, Beyer T, et al. Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA 2006; 296(21): 2590-600
38. Veit P, Kühle C, Beyer T, et al. Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer. Gut 2006; 55(1): 68-73
39. Nagata K, Ota Y, Okawa T, Endo S, Kudo SE. PET/CT colonography for the preoperative evaluation of the colon proximal to the obstructive colorectal cancer. Dis Colon Rectum. 2008; 51(6): 882-90
40. Basu S, Li G, Alavi A. PET and PET-CT imaging of gyneco logical malignancies: present role and future promise. Expert Rev Anticancer Ther 2009; 9(1): 75-96
41. Gu P, Pan LL, Wu S Q, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma A systematic review and meta-analysis. Eur J Radiol 2008
42. Hauth EA, Antoch G, Stattaus J, et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J Radiol 2005; 56(2): 263-8
43. Mangili G, Picchio M, Sironi S, et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging 2007; 34(5): 658-66
44. Thrall MM, DeLoia JA, Gallion H, Avril N.Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 2007; 105(1): 17-22
45. Sebastian S, Lee SI, Horowitz NS, et al. PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging 2008; 33(1): 112-8
46. Sheng XG, Zhang XL, Fu Z, Li HQ, Li QS, Ma ZF, Li DP, Chen ZY. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi 2007; 42(7): 460-3
47. Soussan M, Wartski M, Cherel P, et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovar ian carcinoma recurrence. Gynecol Oncol 2008; 108(1): 160-5
48. Kim CK, Park BK, Choi JY, Kim BG, Han H.Detection of recur rent ovarian cancer MRI: comparison with integrated PET/CT.J Comput Assist Tomogr 2007; 31(6): 868-75